Published date:Mar 24 2025

Journal Title: Dubai Medical Journal

Issue title: Dubai Medical Journal (DMJ): Volume 8, Issue 1

Pages:57 - 72

DOI: 10.18502/dmj.v8i1.18315

Hamid K. Al-TameemiDepartment of Medical Laboratory Technology, College of Medical and Health Technology, University of Bilad Alrafidain, Baqubah, Diyala

Dina A. AbdullahDepartment of Science, College of Basic Education, University of Diyala, Baqubah

Mustafa T. Al-BaldawyDepartment of Medical Laboratory Technology, Technical Institute of Balad, Middle Technical University, Balad

Hussein A. Abidmskc2d@pte.huDepartment of Laboratory Diagnostics, Faculty of Health Sciences, University of Pécs, Pécs

Osama B. Al-SaffarDepartment of Medical Laboratory Technology, Technical Institute of Balad, Middle Technical University, Balad

Hussein Raof Al-GazaliDepartment of Medical Laboratory Techniques, Al-Kafeel University, Najaf

Introduction: Breast cancer is a heterogeneous disease with variable molecular profiles. This study aims to evaluate the expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), phosphatidylinositol-4,5- bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), interleukin-8 (IL-8), and antigen Kiel 67 (Ki-67) in early-stage breast cancer and their associations with clinicopathological features.

Methods: Tissue samples from 93 early diagnosed breast cancer patients, attending Al- Andalus Hospital in Baghdad, Iraq, from February 2022 to April 2023, were analyzed using immunohistochemistry. Expression patterns of the six biomarkers (ER, PR, HER2, PIK3CA, IL-8, and Ki-67) were correlated with tumor grade, histological type, tumor size, and lymph node involvement. Statistical analyses included chi-square and Fisher’s exact tests as well as various correlation coefficients (Pearson, Spearman, and phi).

Results: ER and PR positivity were inversely associated with tumor grade, while HER2, PIK3CA, and Ki-67 showed positive correlations. In addition, invasive ductal carcinomas mainly expressed ER+/PR+ profiles, while invasive lobular carcinomas showed higher rates of HER2 positivity compared to ductal carcinomas. Furthermore, increasing tumor size and higher degrees of lymph node involvement were positively correlated with increased expression of HER2, PIK3CA, and Ki-67. Moreover, a strong positive correlation was observed between IL-8 and Ki-67 expressions.

Discussion: The study reported distinct molecular profiles associated with various clinicopathological features. In particular, well-differentiated tumors predominantly displayed hormone receptor-positive subtypes, while poorly differentiated tumors showed more aggressive molecular profiles. The findings confirm the complex relationship between some biomarkers and tumor characteristics.

Conclusion: The current study’s analysis gives information about the molecular shape of early-stage breast cancer. The reported associations between biomarker expression and clinicopathological features may add to improved prognostic assessment and treatment strategies for breast cancer patients.

Keywords: breast neoplasms, cell proliferation, estrogen receptors, Iraq, tumor biomarkers

[1] Wilkinson L, Gathani T. Understanding breast cancer as a global health concern. British Journal of Radiology. 2022 Feb;95(1130):20211033. https://doi.org/10.1259/bjr.20211033

[2] Raheem AR, Abdul-Rasheed OF, Khattab OS, Alsammarraie AZ, Al-Aubaidy H, Abid HA. Circulating miRNA-373 and vascular endothelial growth factor as potential biomarkers for early detection of breast cancer. Indian J Clin Biochem. 2024 Feb 2; Available from: https://link.springer.com/10.1007/s12291- 023-01174-9 https://doi.org/10.1007/s12291-023-01174-9.

[3] World Health Organization. Breast cancer. Factsheets. 2024. Available from: https://www.who.int/newsroom/ fact-sheets/detail/breast-cancer

[4] Iraqi Cancer Board. Cancer Registry of Iraq: Annual Report. Baghdad, Iraq; 2022. Available from: https://storage.moh.gov.iq/2024/03/31/2024_03_31_11983087032_3940351786864953.pdf

[5] Rakha EA, Green AR. Molecular classification of breast cancer: What the pathologist needs to know. Pathology. 2017 Feb;49(2):111–119. Available from: https://linkinghub.elsevier.com/retrieve/pii/ S003130251640365X

[6] Zhang H, Katerji H, Turner BM, Hicks DG. HER2-low breast cancers. Am J Clin Pathol. 2022 Mar;157(3):328–336. Available from: https://academic.oup.com/ajcp/article/157/3/328/6370127

[7] Scabia V, Ayyanan A, De Martino F, Agnoletto A, Battista L, Laszlo C, et al. Estrogen receptor positive breast cancers have patient specific hormone sensitivities and rely on progesterone receptor. Nat Commun. 2022 Jun;13(1):3127. Available from: https://www.nature.com/articles/s41467-022-30898-0

[8] Li Z, Wei H, Li S, Wu P, Mao X. The role of progesterone receptors in breast cancer. Drug Des Devel Ther. 2022 Jan;16:305–314. Available from: https://www.dovepress.com/the-role-of-progesteronereceptors- in-breast-cancer-peer-reviewed-fulltext-article-DDDT

[9] Iqbal N, Iqbal, N. Human Epidermal growth factor receptor 2 (HER2) in cancers: Overexpression and therapeutic implications. Molecular Biology International. 2014:852748. https://doi.org/10.1155/2014/852748

[10] Mosele F, Stefanovska B, Lusque A, Tran Dien A, Garberis I, Droin N, et al. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. Ann Oncol. 2020 Mar;31(3):377– 386. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0923753419390945

[11] Todorović-Raković N, Milovanović J. Interleukin-8 in breast cancer progression. J Interferon Cytokine Res. 2013 Oct;33(10):563–570. Available from: http://www.liebertpub.com/doi/10.1089/jir.2013.0023

[12] Inwald EC, Klinkhammer-Schalke M, Hofstädter F, Zeman F, Koller M, Gerstenhauer M, et al. Ki-67 is a prognostic parameter in breast cancer patients: Results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat. 2013 Jun;139(2):539–552. Available from: http://link.springer.com/ 10.1007/s10549-013-2560-8

[13] Manjer J, Malina J, Berglund G, Bondeson L, Garne JP, Janzon L. Smoking associated with hormone receptor negative breast cancer. Int J Cancer. 2001 Feb;91(4):580–584. Available from: http://www. ncbi.nlm.nih.gov/pubmed/11251985

[14] Butler EN, Bensen JT, Chen M, Conway K, Richardson DB, Sun X, et al. Prediagnostic smoking is associated with binary and quantitative measures of ER protein and ESR1 mRNA expression in breast tumors. Cancer Epidemiol Biomarkers Prev. 2018 Jan;27(1):67–74. Available from: https://aacrjournals. org/cebp/article/27/1/67/71389/Prediagnostic-Smoking-Is-Associated-with-Binary

[15] Wickham H. ggplot2. Wiley Interdiscip Rev Comput Stat. 2011 Mar;3(2):180–185. Available from: https: //wires.onlinelibrary.wiley.com/doi/10.1002/wics.147

[16] Jovicić-Milentijević M, Ilić R, Katić V, Zivković V. Correlation of steroid hormone receptor status with histological and nuclear grading in breast carcinoma. J Balkan Union Oncol. 2004;9(2):173–177. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17415810

[17] Reddy DP, Devi SD. Correlation of ER, PR, Her2neu and Ki67 with other Prognostic factors in Breast Carcinoma. Trop J Pathol Microbiol. 2020 Jun 30;6(5):349–361. Available from: https://pathology. medresearch.in/index.php/jopm/article/view/459

[18] Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, et al. Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. J Clin Pathol. 2005 Jun;58(6):611–616. Available from: https://jcp.bmj.com/ lookup/doi/10.1136/jcp.2004.022772

[19] Swede H, Moysich KB, Winston JS, Hurd TC, Edge SB, Romero-Gutierrez M, et al. Variation of the prognostic significance of HER-2 expression in breast cancer according to tumor size. Breast J. 2003;9(2):98–105. Available from: http://doi.wiley.com/10.1046/j.1524-4741.2003.09207.x

[20] Tokatli F, Altaner S, Uzal C, Ture M, Kocak Z, Uygun K, et al. Association of HER-2/neu overexpression with the number of involved axillary lymph nodes in hormone receptor positive breast cancer patients. Exp Oncol. 2005 Jun;27(2):145–149. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15995634

[21] Kee GJ, Tan RY, Rehena S, Lee JJ, Zaw MW, Lian WX, et al. Human epidermal growth factor receptor 2 positive rates in invasive lobular breast carcinoma: The Singapore experience. World J Clin Oncol. 2020 May;11(5):283–293. Available from: https://www.wjgnet.com/2218-4333/full/v11/i5/283.htm

[22] Aleskandarany MA, Rakha EA, Ahmed MA, Powe DG, Paish EC, Macmillan RD, et al. PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis. Breast Cancer Res Treat. 2010 Jul;122(1):45– 53. Available from: http://link.springer.com/10.1007/s10549-009-0508-9